Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2012

01-01-2012 | Brief Report

Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival

Authors: Verena Varadi, Melanie Bevier, Ewa Grzybowska, Robert Johansson, Kerstin Enquist-Olsson, Roger Henriksson, Dorota Butkiewicz, Jolanta Pamula-Pilat, Karolina Tecza, Kari Hemminki, Per Lenner, Asta Försti

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Abstract

Chromosomal instability is a hallmark of many cancers and it has a potential to predict clinical outcome of a cancer patient. We hypothesized that genes whose expression status differs between chromosomal stable and unstable breast tumors represent target genes for the identification of genetic variants predicting breast cancer (BC) risk, disease progression, and survival. We used a published list of 38 genes associated with chromosomal instability as a basis for searching potentially functional and informative tagging single nucleotide polymorphisms (SNPs). As a result, 33 SNPs in 16 genes were genotyped in a population-based series of 783 Swedish BC cases. Two SNPs in the ALCAM gene associated with BC-specific survival. For rs1044243, the HR was 4.35 (95% CI 1.34–14.18), and for rs1157, the HR was 3.42 (95% CI 1.32–8.83) for the homozygous carriers of the minor alleles. For the minor allele carriers of CCL18 SNP rs14304, we observed a significant association with aggressive tumor characteristics: large tumor size (OR 1.53, 95% CI 1.10–2.14), positive lymph node metastasis (OR 1.75, 95% CI 1.02–3.00), and high stage (OR 1.37, 95% CI 1.02–1.85). In a Polish population consisting of 506 familial/early onset BC cases, no association with event-free survival for the ALCAM SNPs nor any association with tumor characteristics for the CCL18 SNP were observed, suggesting either a chance finding in the Swedish population or population-based or etiological differences between sporadic and familial/early onset BC.
Literature
2.
go back to reference Wittschieben JP, Reshmi SC, Gollin SM, Wood RD (2006) Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res 66(1):134–142PubMedCrossRef Wittschieben JP, Reshmi SC, Gollin SM, Wood RD (2006) Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res 66(1):134–142PubMedCrossRef
3.
go back to reference Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38(9):1043–1048PubMedCrossRef Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38(9):1043–1048PubMedCrossRef
4.
go back to reference Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Kruger S, Bruch HP, Auer G, Guo NL, Ried T (2009) The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 124(7):1552–1564PubMedCrossRef Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Kruger S, Bruch HP, Auer G, Guo NL, Ried T (2009) The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 124(7):1552–1564PubMedCrossRef
5.
go back to reference Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C (2011) Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 71(10):3447–3452PubMedCrossRef Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C (2011) Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 71(10):3447–3452PubMedCrossRef
6.
go back to reference Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Szallasi Z, Kschischo M, Swanton C (2011) Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-11-0343 Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Szallasi Z, Kschischo M, Swanton C (2011) Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiol Biomarkers Prev. doi:10.​1158/​1055-9965.​EPI-11-0343
7.
go back to reference Mettu RK, Wan YW, Habermann JK, Ried T, Guo NL (2010) A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers 25(4):219–228 Mettu RK, Wan YW, Habermann JK, Ried T, Guo NL (2010) A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers 25(4):219–228
8.
go back to reference Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13(4):307–316PubMedCrossRef Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13(4):307–316PubMedCrossRef
9.
go back to reference Brendle A, Brandt A, Johansson R, Enquist K, Hallmans G, Hemminki K, Lenner P, Forsti A (2009) Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study. Eur J Cancer 45(3):435–442PubMedCrossRef Brendle A, Brandt A, Johansson R, Enquist K, Hallmans G, Hemminki K, Lenner P, Forsti A (2009) Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study. Eur J Cancer 45(3):435–442PubMedCrossRef
10.
go back to reference Varadi V, Brendle A, Brandt A, Johansson R, Enquist K, Henriksson R, Svenson U, Tavelin B, Roos G, Hemminki K, Lenner P, Forsti A (2009) Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis. Eur J Cancer 45(17):3008–3016PubMedCrossRef Varadi V, Brendle A, Brandt A, Johansson R, Enquist K, Henriksson R, Svenson U, Tavelin B, Roos G, Hemminki K, Lenner P, Forsti A (2009) Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis. Eur J Cancer 45(17):3008–3016PubMedCrossRef
11.
go back to reference Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812–3814PubMedCrossRef Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812–3814PubMedCrossRef
12.
go back to reference Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11(5):863–874PubMedCrossRef Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11(5):863–874PubMedCrossRef
13.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265PubMedCrossRef Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265PubMedCrossRef
14.
go back to reference Swart GW (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81(6):313–321PubMedCrossRef Swart GW (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81(6):313–321PubMedCrossRef
15.
go back to reference Chen JM, Ferec C, Cooper DN (2006) A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3′UTR variants. Hum Genet 120(3):301–333PubMedCrossRef Chen JM, Ferec C, Cooper DN (2006) A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3′UTR variants. Hum Genet 120(3):301–333PubMedCrossRef
16.
go back to reference Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K (2008) Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112(3):419–427PubMedCrossRef Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K (2008) Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112(3):419–427PubMedCrossRef
17.
go back to reference Davies S, Jiang WG (2010) ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res 30(4):1163–1168PubMed Davies S, Jiang WG (2010) ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res 30(4):1163–1168PubMed
18.
go back to reference King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6(5):R478–R487PubMedCrossRef King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6(5):R478–R487PubMedCrossRef
19.
go back to reference Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, Anderson KS, Liu Q, Ewen ME, Yao X, Song E (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19(4):541–555 Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, Anderson KS, Liu Q, Ewen ME, Yao X, Song E (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19(4):541–555
20.
go back to reference Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220–228PubMedCrossRef Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220–228PubMedCrossRef
21.
go back to reference Endesfelder D, McGranahan N, Birkbak NJ, Szallasi Z, Kschischo M, Graham TA, Swanton C (2011) A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget 2(7):529–537PubMed Endesfelder D, McGranahan N, Birkbak NJ, Szallasi Z, Kschischo M, Graham TA, Swanton C (2011) A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget 2(7):529–537PubMed
Metadata
Title
Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival
Authors
Verena Varadi
Melanie Bevier
Ewa Grzybowska
Robert Johansson
Kerstin Enquist-Olsson
Roger Henriksson
Dorota Butkiewicz
Jolanta Pamula-Pilat
Karolina Tecza
Kari Hemminki
Per Lenner
Asta Försti
Publication date
01-01-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1765-y

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine